MK761

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525653

CAS#: 65321-41-7

Description: MK761 is a new class of compound which has beta adrenoceptor antagonist and vasodilating properties in a single molecule. The compound has in vitro beta adrenoceptor blocking activity in the isolated cat heart papillary muscle and isolated rat atria. It is approximately as potent as timolol and pindolol in blocking cardiac and vascular beta adrenergic receptors.

Chemical Structure

img
MK761
CAS# 65321-41-7
Instruction

Theoretical Analysis

MedKoo Cat#: 525653
Name: MK761
CAS#: 65321-41-7
Chemical Formula: C13H19N3O2
Exact Mass: 249.15
Molecular Weight: 249.309
Elemental Analysis: C, 62.63; H, 7.68; N, 16.85; O, 12.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MK-761; MK 761; MK761

IUPAC/Chemical Name: (S)-2-(3-(tert-butylamino)-2-hydroxypropoxy)nicotinonitrile

InChi Key: KVTGTAZVDSYIPY-NSHDSACASA-N

InChi Code: InChI=1S/C13H19N3O2/c1-13(2,3)16-8-11(17)9-18-12-10(7-14)5-4-6-15-12/h4-6,11,16-17H,8-9H2,1-3H3/t11-/m0/s1

SMILES Code: N#CC1=CC=CN=C1OC[C@@H](O)CNC(C)(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 249.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sweet CS, Hall RA, Columbo JM, Wenger HC, Backlund E, Morgan G, Gaul SL, Scriabine A. Beta adrenoceptor blocking properties of MK-761. J Pharmacol Exp Ther. 1979 Oct;211(1):195-9. PubMed PMID: 40012.
2: Sweet CS, Scriabine A, Weitz D, Ludden CT, Minsker DH, Stone CA. Antihypertensive and hemodynamic properties of 2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine HCl (MK-761). J Pharmacol Exp Ther. 1979 Oct;211(1):200-6. PubMed PMID: 114619.
3: Mostaghim R, Maddox YT, Ramwell PW. Endothelial potentiation of relaxation response to beta adrenoceptor blocking agents. J Pharmacol Exp Ther. 1986 Dec;239(3):797-801. PubMed PMID: 2879033.
4: Scriabine A, Ludden CT, Morgan G, Baldwin JJ. Antihypertensive and cardiac effects of two novel beta-adrenoceptor blocking drugs. Experientia. 1979 Dec 15;35(12):1634-7. PubMed PMID: 42553.
5: Sybertz EJ, Baum T, Pula KK, Nelson S, Eynon E, Sabin C. Studies on the mechanism of the acute antihypertensive and vasodilator actions of several beta-adrenoceptor antagonists. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):749-58. PubMed PMID: 6182405.
6: Lefer AM, Lefer DJ, Levin RJ. Actions of non-cardiodepressant beta-adrenergic blocking agents in hemorrhagic shock. Adv Shock Res. 1980;3:167-74. PubMed PMID: 6118024.
7: Baum T, Sybertz EJ. Antihypertensive actions of an isomer of labetalol and other vasodilator-beta-adrenoceptor blockers. Fed Proc. 1983 Feb;42(2):176-81. PubMed PMID: 6130003.
8: Vickers S, Duncan CA, Arison BH, Davies RO, Ferguson R, Zacchei AG. The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans. Drug Metab Dispos. 1980 May-Jun;8(3):163-7. PubMed PMID: 6104580.
9: McClure DE, Baldwin JJ, Randall WC, Lyon TF, Mensler K, Lundell GF, Raab AW, Gross D, Risley EA, Sweet CS, Williams M. Antihypertensive beta-adrenergic blocking agents: N-aralkyl analogues of 2-[3-(tert-butylamino)-2-hydroxypropoxy]-3-cyanopyridine. J Med Chem. 1983 May;26(5):649-57. PubMed PMID: 6132999.